[Skip to Navigation]
Sign In
April 4, 2024

Introducing the JAMA Summit

Author Affiliations
  • 1Editor in Chief, JAMA and Ƶ
  • 2Critical Care Medicine, UPMC, Pittsburgh, Pennsylvania
  • 3Senior Editor, JAMA
  • 4Managing Director of Strategy and Planning, JAMA and Ƶ
  • 5Department of Emergency Medicine, Harbor-UCLA Medical Center, Torrance, California
  • 6Statistical Editor, JAMA
  • 7Cardiovascular Medicine, Yale School of Medicine, New Haven, Connecticut
  • 8Associate Editor, JAMA
  • 9Director, Communications and Engagement, JAMA and Ƶ
  • 10Executive Managing Editor, JAMA and Ƶ
  • 11Executive Editor, JAMA and Ƶ
JAMA. 2024;331(17):1451. doi:10.1001/jama.2024.5570

Over the past year, JAMA editors have been developing the concept of the JAMA Summit—forums for catalyzing discussion and action on pressing issues in science, medicine, and public health. Over its more than 140-year history, JAMA has been a leader in publishing on critical issues related to health. As a forum for eliciting new ideas, facilitating cross-sector dialogue, and identifying opportunities for progress that inspire discussion and action, the JAMA Summit represents the latest iteration of this long tradition of furthering our mission to advance the science and art of medicine and the betterment of public health.

JAMA Summits have 2 phases:

  1. Convening thought leaders from across sectors relevant to the specific topic of the JAMA Summit. The focus of these meetings is on dialogue, discussion, and debate, with the goal of eliciting themes and identifying actionable steps that can have a positive impact on a short time horizon.

  2. Elaborating on the themes identified during the in-person or virtual gatherings through published articles and multimedia in JAMA and the Ƶ journals. This phase also extends the discussion of the specific topic to the broader biomedical community through a call for papers and an invitation to broader dialogue across the platform of the Ƶ.

The inaugural JAMA Summit was held in October 2023 in Chicago and was focused on randomized clinical trials, the foundation of evidence-based medicine, addressing the provocative questions: “Is the clinical trials enterprise broken? And how can it be fixed?” Sixty-five individuals from around the world attended this in-person meeting, including researchers, funders, regulators, patient advocates, policymakers, innovators, and industry representatives. Over 2 days, 3 keynote addresses, and 5 panel presentations and discussions, the challenges and opportunities to improve the design and conduct of randomized clinical trials to be most responsive to the needs in clinical practice were dissected and debated.

This JAMA Summit on integrating clinical trials and practice will soon enter the second phase, and JAMA will begin publication on several of the themes developed during this convergence. JAMA will also issue a broader call for papers on clinical trials and invite further exploration of approaches to improving the conduct of clinical trials and the uptake of trial evidence in clinical practice.

Our next JAMA Summit will focus on the integration of artificial intelligence (AI) in clinical care and will begin in the fall of 2024 with an in-person assembly. The conversations in this meeting will address the strategies essential to realizing the immense promise of AI while addressing the key barriers to its safe and equitable integration into care processes. We are actively planning other JAMA Summits, including on the topic of firearms and violence prevention, another complex and critical health challenge.

How can you get involved? We welcome input on the JAMA Summits currently underway, as well as suggestions for topics that may be the focus of future JAMA Summits. We invite you to share your comments at events@jamanetwork.org and follow the JAMA Summit website for updates.

Back to top
Article Information

Corresponding Author: Kirsten Bibbins-Domingo, PhD, MD, MAS, JAMA (kirsten.bibbins-domingo@jamanetwork.org).

Published Online: April 4, 2024. doi:10.1001/jama.2024.5570

Conflict of Interest Disclosures: Dr Lewis reported serving as senior medical scientist at Berry Consultants LLC, a statistical consulting firm focusing on the design, implementation, and analysis of adaptive and platform clinical trials. Dr Khera reported receiving grants from the National Heart, Lung, and Blood Institute, from Doris Duke Charitable Foundation, from Bristol Myers Squibb through Yale, from Novo Nordisk through Yale, from BridgeBio through Yale; and serving as an academic cofounder of Evidence2Health and Ensight-AI, outside the submitted work. No other disclosures were reported.